Advanced Oncotherapy (LON:AVO) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk.
Martin updates us on some of the recent developments at the company, explains why the share price is languishing, the demand for the project, shares his thoughts on the success of LIGHT and the company valuation.
Advanced Oncotherapy plc is a UK-based company focused on delivering a cost-effective proton-based radiotherapy solution called LIGHT. Based on ground-breaking technology developed and tested at world renowned CERN in Switzerland, the LIGHT system delivers an integrated proton radiotherapy system to treat cancer.